2022 a good year for Sobi

8 February 2023

Swedish Orphan Biovitrum (STO: SOBI), also known as Sobi, today released financial results for the fourth-quarter and full-year 2022, that were seen as positive by investors, with the firm’s shares rising 2.9% to 242.20 kronor.

The company noted that total revenue for the quarter was 5,991 million Swedish kronor ($1.18 billion), an increase of 22% and up 5% at constant exchange rates (CER. Earnings before interest, taxes and amortization (EBIT) was 2,455 million kronor. Earnings per share (EPS) before dilution were 4.68 kronor, a rise of 11%. (4.21).

For the full year, total revenues were 18,790 million kronor, +21% and +8% at CER. EPS before dilution was 8.92 kronor, down1.8%, and EPS adjusted before dilution was 10.77, up 19%. (9.08).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK